The Centre Multidisciplinaire de Développement du Génie Tissulaire (CMDGT) and the CHU de Québec Research Centre recently announced they have successfully grafted cultured, living corneal substitutes created in laboratory through tissue engineering. CMDGT is the first medical facility in Canada to transplant patients’ own living tissues (autologous) to replace a corneal epithelium (the tissues covering the front of the cornea).
CellCAN is a Canadian network focused on advancing cell and gene therapy manufacturing under GMP through the deployment of standards for training that implement best practices.